Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Transplantation and Cellular Therapy|May 20, 2026
High incidence of cytomegalovirus infection in patients receiving standard of care CD19- or BCMA-targeted CAR T-cell therapies for hematologic malignanciesTamer Othman, John H Baird, Yan Wang, et al.
Cancer Medicine|December 18, 2021
Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myelomaDarren Pan, Jonathan L Kaufman, Myo Htut, et al.
Transplantation and Cellular Therapy|June 13, 2024
Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) TherapyScott R Goldsmith, Geoffrey Shouse, F Lennie Wong, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 10, 2023
Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's LymphomaMatthew Mei, Joycelynne Palmer, Nicole Ni-Chun Tsai, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 16, 2023
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 StudyMyo Htut, Binod Dhakal, Adam D Cohen, et al.
Cancer|July 20, 2016
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myelomaAjai Chari, Myo Htut, Jeffrey A Zonder, et al.
Leukemia|February 22, 2020
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myelomaAmrita Krishnan, Prashant Kapoor, Joycelynne M Palmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2017
Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple MyelomaXiuli Wang, Miriam Walter, Ryan Urak, et al.
Nature Medicine|January 23, 2023
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim resultsSham Mailankody, Jeffrey V Matous, Saurabh Chhabra, et al.
American Journal of Hematology|September 5, 2023
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphomaShin Yeu Ong, Stacy Pak, Matthew Mei, et al.
Pageof 5